

1 **Title:** ClinGen Variant Curation Interface: A Variant Classification Platform for the Application  
2 of Evidence Criteria from ACMG/AMP Guidelines

3

4 **Short Title:** ClinGen Variant Curation Interface (VCI)

5

6 **Authors:** Christine G. Preston<sup>1#</sup>, Matt W. Wright<sup>1#</sup>, Rao Madhavrao<sup>1</sup>, Steven M. Harrison<sup>2</sup>,  
7 Jennifer L. Goldstein<sup>3</sup>, Xi Luo<sup>4</sup>, Hannah Wand<sup>5</sup>, Bryan Wulf<sup>1</sup>, Gloria Cheung<sup>1</sup>, Mark E.  
8 Mandell<sup>1</sup>, Howard Tong<sup>1</sup>, Shaung Cheng<sup>1</sup>, Michael A. Iacocca<sup>1</sup>, Arturo Lopez Pineda<sup>6</sup>, Alice B.  
9 Popejoy<sup>6</sup>, Karen Dalton<sup>7</sup>, Jimmy Zhen<sup>7</sup>, Selina S. Dwight<sup>8</sup>, Lawrence Babb<sup>2</sup>, Marina DiStefano<sup>2</sup>,  
10 Julianne M. O'Daniel<sup>3</sup>, Kristy Lee<sup>3</sup>, Erin R. Riggs<sup>9</sup>, Diane B. Zastrow<sup>10</sup>, Jessica L. Mester<sup>11</sup>,  
11 Deborah I. Ritter<sup>4</sup>, Ronak Y. Patel<sup>12</sup>, Sai Lakshmi Subramanian<sup>12</sup>, Aleks Milosavljevic<sup>12</sup>,  
12 Jonathan S. Berg<sup>3</sup>, Heidi L. Rehm<sup>2,13</sup>, Sharon E. Plon<sup>4,12</sup>, J. Michael Cherry<sup>14</sup>, Carlos D.  
13 Bustamante<sup>6,14</sup>, Helio A. Costa<sup>1,6\*</sup>, on behalf of the Clinical Genome (ClinGen) Resource

14

15 **Affiliations:**

16 <sup>1</sup>Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305 USA

17 <sup>2</sup>Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA 02142

18 USA

19 <sup>3</sup>Department of Genetics, University of North Carolina, Chapel Hill, NC 27599 USA

20 <sup>4</sup>Department of Pediatrics/Hematology-Oncology, Baylor College of Medicine, Houston, TX

21 77030 USA

22 <sup>5</sup>Center for Inherited Cardiovascular Disease, Stanford Health Care, Stanford, CA 94305 USA

23 <sup>6</sup>Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA

24 94305 USA

25 <sup>7</sup>Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305 USA

26 <sup>8</sup>Grace Science LLC, Menlo Park, CA 94025 USA

27 <sup>9</sup>Autism & Developmental Medicine Institute, Geisinger Health System, Lewisburg, PA 17837

28 USA

29 <sup>10</sup>Sutter Health, Mountain View, CA 94040 USA

30 <sup>11</sup>GeneDx Inc., Gaithersburg, MD 20877 USA

31 <sup>12</sup>Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX

32 77030 USA

33 <sup>13</sup>Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA

34 <sup>14</sup>Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305 USA

35 #These authors contributed equally to this work

36 \*Correspondence to: Helio A. Costa, Ph.D. (H.A.C.), Stanford University, Department of

37 Pathology, 300 Pasteur Drive, MSOB x313, Stanford, CA 94305. Email: hcosta@stanford.edu

38

39 **Keywords:** Variant Curation; Precision Medicine; Medical Genetics; Clinical Genome Resource

40 Consortium

41

42 **Tables:** 1

43

44 **Figures:** 6

45

46 **Sources of support:** This research was funded by grants from the National Human Genome  
47 Research Institute (NHGRI) of the National Institutes of Health (U41HG009649,  
48 U01HG007436, U41HG006834, U01HG007434, U41HG009650).

49

50 **Disclosure:** S.E.P. is a member of the Baylor Genetics Scientific Advisory Panel. A.M. is an  
51 employee of Baylor College of Medicine (BCM) and performs integration consulting services for  
52 BCM-developed software including Genboree through IP Genesis Inc. C.D.B. is on the scientific  
53 advisory boards (SAB) of AncestryDNA, Arc Bio LLC, Etalon DX, Liberty Biosecurity, and  
54 Personalis. C.D.B. is on the board of EdenRoc Sciences LLC. C.D.B. is also a founder and SAB  
55 chair of ARCBio. J.L.M. is an employee of GeneDx/BioReference Laboratories, Inc./OPKO  
56 Health and has a salary as the only disclosure. None of these entities played a role in the design,  
57 execution, interpretation, or presentation of this study.

58

59 **Abstract:**

60

61 **Background:** Identification of clinically significant genetic alterations involved in human  
62 disease has been dramatically accelerated by developments in next-generation sequencing  
63 technologies. However, the infrastructure and accessible comprehensive curation tools necessary  
64 for analyzing an individual patient genome and interpreting genetic variants to inform healthcare  
65 management have been lacking. **Results:** Here we present the ClinGen Variant Curation  
66 Interface (VCI), a global open-source variant classification platform for supporting the  
67 application of evidence criteria and classification of variants based on the ACMG/AMP variant  
68 classification guidelines. The VCI is among a suite of tools developed by the NIH-funded  
69 Clinical Genome Resource (ClinGen) Consortium, and supports an FDA-recognized human  
70 variant curation process. Essential to this is the ability to enable collaboration and peer review  
71 across ClinGen Expert Panels supporting users in comprehensively identifying, annotating, and  
72 sharing relevant evidence while making variant pathogenicity assertions. To facilitate evidence-  
73 based improvements in human variant classification, the VCI is publicly available to the  
74 genomics community and is available at <https://curation.clinicalgenome.org>. Navigation  
75 workflows support users providing guidance to comprehensively apply the ACMG/AMP  
76 evidence criteria and document provenance for asserting variant classifications. **Conclusion:** The  
77 VCI offers a central platform for clinical variant classification that fills a gap in the learning  
78 healthcare system, and facilitates widespread adoption of standards for clinical curation.

79

80 **Introduction:**

81

82 The application of genomics to precision medicine holds great promise for the implementation of  
83 tailored diagnostics, optimized patient care management, and personalized therapies in  
84 healthcare. The past decade has seen the development of technological and computational  
85 innovations to bring both DNA-sequencing methodologies and bioinformatic algorithms into  
86 routine standard-of-care for diagnostic medical genomics. While there has been broad consensus  
87 in terms of bioinformatic best practices, quality control metrics, and community adoption of  
88 variant calling and classification standards, substantial variability remains among variant  
89 curation tools and data sharing by health care providers, clinical diagnostic laboratories, and  
90 researchers.

91 Clinical interpretation of genomic sequencing data requires both the standardization of variant  
92 classification guidelines, as well as consistency in the workflow and evidence considered when  
93 determining the relationship between a variant and a disease phenotype. Since the 2015 release  
94 of the American College of Medical Genetics and Genomics / Association for Molecular  
95 Pathology (ACMG/AMP) guidelines<sup>1</sup>, the genomics community has substantially adopted<sup>2</sup> the  
96 standards outlined by Richards *et al.* and the guidance provided by the Clinical Genome  
97 Resource (ClinGen) Consortium<sup>3</sup> to aid in further refining and standardizing the evaluation of  
98 sequence variant pathogenicity<sup>4-16</sup>.

99 While the creation of these variant classification guidelines and standards is a central objective,  
100 there is also a significant unmet need for computational infrastructure and curation software to  
101 guide biocurators through these complex curation workflows. Here we present the ClinGen  
102 Variant Curation Interface (VCI), which is a comprehensive variant classification platform

103 designed to support both individual and group classification in accordance with the ACMG/AMP  
104 guidelines. The VCI is intended to be a publicly available variant curation tool which  
105 programmatically guides users through a standard process for variant evidence classification and  
106 application of ACMG/AMP guidelines in a controlled workflow to enforce rigor and quality in  
107 variant classification (**Figure 1**).

108

### 109 **Implementation:**

110

111 The VCI curation platform has been developed to facilitate the FDA-recognized ClinGen variant  
112 classification process, support transparent evidence review, and provide timely dissemination to  
113 the genomics community. Users can curate individually or communally in groups known as  
114 affiliations. The VCI programmatically displays relevant data types from external sources  
115 (**Table 1**), and displays evidence identified by other VCI users in an organized user interface  
116 enabling an environment to document ACMP/AMP criteria codes.

117

118 The core elements of the VCI data model are shown in **Figure 2**. The full data model is stored in  
119 Javascript Object Notation (JSON) format with references to data elements. The data model is  
120 centered upon a variant classification, with attributes consisting of data and context related to  
121 asserting the variant's pathogenicity. The classification model is based on the combined variant,  
122 disease, and mode of inheritance data models. Each variant is evaluated by biocurators against  
123 specific evidence types which are reflected in the VCI's data models, (e.g. population data,  
124 experimental data, computational data), as well as literature-based evidence which can be  
125 manually added by a biocurator and related to any of the other evidence types. Biocurator-

126 selected evaluations of the evidence criteria provide a computed variant pathogenicity, which can  
127 be manually overridden by biocurators based on expert opinion consistent with the ACMG/AMP  
128 guidelines.

129  
130 The classification model is designed to support the ClinGen workflow of variant curation, which  
131 is an iterative and manual process, with biocurators making criteria evaluations, and expert  
132 panels considering and approving final classifications. This is modeled in the platform in two  
133 ways, first each variant classification has a status attribute that indicates the most recent status of  
134 the classification, ('In-progress', 'Provisional', 'Approved', 'Published', 'New-Provisional').  
135 Secondly, the classification model only stores references to its related models (e.g. variant,  
136 disease, evidence, evidence criteria), which also store the most recent information. When a  
137 classification has a status of 'Provisional', 'Approved' or 'Published', the snapshot model is used  
138 to store an instance (point in time) containing all of the related data. This allows changes to the  
139 related data to be identified, while previous data, which may have been used to make a criteria  
140 evaluation, are still preserved in the snapshot. Snapshots published to ERepo and ClinVar  
141 undergo a transformation to SEPIO (<http://dataexchange.clinicalgenome.org/interpretation/index.html>).

142  
143 The VCI is accessed through a web browser where users can perform curation activities  
144 including review of imported evidence, entry of evidence gathered from published and  
145 unpublished sources, ACMG/AMP criteria application, pathogenicity evaluation, and  
146 classification review and approval. The classified variants from ClinGen-approved Variant  
147 Curation Expert Panels (VCEPs) are then shared with the ClinGen Evidence Repository (ERepo;

148 <https://erepo.clinicalgenome.org/>) and the ClinVar database  
149 (<https://www.ncbi.nlm.nih.gov/clinvar/>) to enable peer review and public access.

150  
151 The software for the VCI is freely and openly available via publicly accessible web pages and a  
152 publicly available GitHub repository (<https://github.com/ClinGen/clincoded/>). The VCI website  
153 (<https://curation.clinicalgenome.org>) is developed as a common interface for both the VCI and  
154 the related Gene Curation Interface (GCI), using the same platform and sharing components such  
155 as a user database and classification data. User access to the VCI and GCI is available by  
156 authenticated login. Login permissions are required in order to document the provenance of  
157 evidence added to the interfaces.

158  
159 Users access the VCI web application via the browser and execute the workflow tasks needed to  
160 perform variant curation. The current deployment, VCI v2.0, utilizes cloud-based web  
161 development best practices and a “serverless architecture”, which is a cloud development  
162 approach where all application resource management and scaling needs are automatically  
163 determined and handled by the cloud services. All of the components essential for the application  
164 including authentication, gateways to receive and respond to browser requests, microservices,  
165 and storage are provided by Amazon Web Services (AWS). This scalable and robust architecture  
166 is based on several AWS serverless components shown in **Figure 3**, the role of key components  
167 are further described here. The API Gateway handles tens of thousands of requests per second  
168 and provides automatic schema validation of data, ensuring data integrity in the VCI. Lambda  
169 spawns microservices to store or retrieve data, managing and scaling the computing resources  
170 required by the VCI. DynamoDB is a flexible, document-based database that provides constant



171 load-independent performance, supporting the VCI in long-term goals of scaling to large  
172 numbers of variant classifications and providing bulk variant curation support, while S3 stores  
173 the large VCI database. Additionally, Cognito is used for user management, and Amplify for  
174 web content integration with backend microservices. The user interfaces are created using  
175 standard JavaScript programming (ReactJS) and they obtain information from the database via  
176 an Application Programming Interface (API) using a standard JSON format. For comparison,  
177 this continuous integration and deployment provides greater reliability and cost-savings relative  
178 to the initial deployment of the VCI v1.0 built following a classical three-tier architecture with a  
179 web-frontend component (ReactJS), backend business logic layer (Python and Pyramid), a split  
180 persistence layer containing the state and metadata database (PostgreSQL) and search indexes  
181 (AWS Elasticsearch).

182

183 Services components include an external resource manager, which is responsible for obtaining  
184 data from external sources (**Table 1**) that feed into the variant, gene, disease, population,  
185 predictive, functional and gene data models.

186

187 Finally, ClinGen provides supplemental resources for VCI users including general information  
188 about biocuration, summary videos outlining the concepts and methods behind biocuration, and  
189 links to biocuration resources such as ClinGen's documented standard operating procedures  
190 (<https://clinicalgenome.org/curation-activities/variant-pathogenicity/>).

191

192 *Development Process*

193

194 The VCI software and product development teams worked alongside the ClinGen Variant  
195 Curation Interface Task Team to develop the initial platform. This product was designed through  
196 a user engagement process and VCI v1.0 was launched for use in September 2016, with new  
197 features developed and released monthly. The completely re-architected and updated VCI v2.0  
198 platform was launched in December 2020, and is the current production version.

199 VCI development continues to evolve with the input of core members of the ClinGen variant  
200 curation community that meet twice per month with the VCI development team. This group  
201 includes members of the ClinGen Sequence Variant Interpretation (SVI) Working Group, which  
202 provides guidance on how to interpret, refine, and standardize the ACMG/AMP guidelines<sup>5-</sup>  
203 <sup>7,11,16</sup>, and members of ClinGen's Variant Curation Expert Panels (VCEPs). Additional guidance  
204 for VCI development comes from the ClinGen Data Access, Protection and Confidentiality  
205 (DAPC) Working Group, which reviews tools and data practices in the ClinGen curation  
206 ecosystem to ensure that software development efforts are informed by updated data sharing  
207 policies. Detailed best practice recommendations for biocurator use of the VCI and associated  
208 resources for variant classification are provided in the ClinGen Variant Curation Standard  
209 Operating Procedure.

### 210 *Variant Identification and Evidence*

211 It is possible to define a variant in several different ways. This promiscuity arises as a result of  
212 the availability of multiple transcripts and genomic reference sequences and various ways to  
213 describe insertion/deletions. As a result, unambiguous identification of variants is critical to the  
214 downstream usability of the curated data. The VCI identifies a variant by either a ClinVar  
215 Variation ID<sup>17</sup> or a ClinGen Allele Registry ID<sup>18</sup>. The variant is then associated with a Mondo

216 Disease Ontology<sup>18</sup> term and a Human Phenotype Ontology<sup>19</sup> mode of inheritance term by the  
217 biocurator or VCEP. Recognizing that a variant can be curated for more than one potential  
218 disease, each user is restricted to one variant classification record per variant. Within the  
219 interfaces each variant is titled based on a hierarchy of naming conventions, preferentially using  
220 a title based on the MANE Select<sup>20</sup> transcript when available (**Figure 4A**).

221 The VCI aggregates and displays multiple types of evidence about a variant, separated into six  
222 tabs structured by data type, providing a rich and structured evidence gathering experience to  
223 biocurators, while supporting variant classification in accordance with the ACMG/AMP  
224 guidelines. This promotes consistency in terms of the evidence evaluated, application of the  
225 ACMG/AMP criteria, and pathogenicity calculations. In keeping with the ClinGen goal to  
226 support appropriate community data sharing, all evidence added by users is viewable by any  
227 other VCI user. While all evidence is viewable by all users, a user's evidence evaluations and  
228 pathogenicity calculations remain private until the classification record has been finalized (set to  
229 'Approved' status), at which point other users can view, but not edit the final classification in the  
230 VCI.

231

### 232 Automated Evidence

233

234 The VCI programmatically retrieves and displays many different types of evidence for each  
235 variant (**Table 1**). This includes the many possible variant nomenclatures on different transcripts  
236 and human genome builds, population frequency data, *in silico* prediction scores, conservation  
237 data, gene and protein resources, and all classifications and submissions for the variant currently  
238 present in ClinVar or the VCI. When evidence is unavailable for direct display via API, dynamic

239 links to external information sources are embedded within the relevant evidence tab. Relevant  
240 external information sources are identified in conjunction with core members of the ClinGen  
241 variant curation community described above.

242

### 243 Manually-Curated Evidence and Structured Data Capture

244

245 Users can manually add information relevant to the variant being classified from published  
246 articles for any evidence type into the relevant sections in the VCI. Additionally, structured data  
247 capture is supported for published functional data, and for published and unpublished case and  
248 segregation evidence. Such structured data inputs ensure curation consistency, as they organize  
249 and accurately define the information so that it can easily be retrieved, facilitate searching of the  
250 captured data, and enable downstream data processing applications such as data mining and  
251 machine learning. Two examples of structured data capture within the VCI are outlined below  
252 (Functional Data Capture and Case Level Data Capture).

253

#### 254 Functional Data Capture

255

256 The ACMG/AMP guidelines require the assessment of well established *in vivo* or *in vitro*  
257 functional studies showing ‘no damaging effect’ (BS3) or ‘supportive of damaging effect’ (PS3)  
258 on protein function or splicing. We have developed a structured framework with the narrative  
259 of 1) method, 2) material, and 3) effect (with or without a quantifier), using standardized  
260 terminology from ontologies, in order for users to define the functional data they have derived  
261 from published articles in a consistent and reproducible way. We provide users with a

262 standardized template for capturing these structured data which they can then submit to  
263 ClinGen's Functional Data Repository (FDRRepo [<https://ldh.genome.network/fdr/ui/>]);  
264 subsequently, these granular functional data for each variant are viewable in the 'Experimental'  
265 tab in the VCI. Future enhancements will include updating the structured narrative and data  
266 fields in accordance with new standards<sup>7</sup> and augmenting capacity for bulk annotations to be  
267 imported from literature annotations or databases of functional evidence including the increasing  
268 availability of data from multiplex assays of variant effect<sup>21,22</sup>.

269

### 270 Case Level Data Capture

271

272 Case level and segregation level data are critical to pathogenicity evaluations using the  
273 ACMG/AMP guidelines. However, individual case observations have the potential to be linked  
274 to individual patient identities if enough ancillary information is also included about the case. It  
275 is for this reason that the case-segregation tab of the VCI prompts users to remember the Terms  
276 of Use for this tool, which include prohibitions on entering protected health information (PHI) or  
277 other sensitive information that could possibly identify an individual data subject, and entering  
278 only the minimum necessary information to resolve a particular case. In order to further protect  
279 data subjects from the possibility of re-identification (which is also strictly prohibited for users of  
280 the VCI as stated in the Terms of Use), individual case-level data are not made publicly available  
281 through ClinGen tools except in aggregate. When entering in case observations or pedigree  
282 segregation evidence, users are directed to a form that has separate fields to capture each distinct  
283 case-level observation or co-segregation events. Then, individual counts for each distinct data

284 type are summed together and analyzed in aggregate along with the same information from other  
285 evidence sources (**Figure 5B**).

286

### 287 Curation Workflow

288

289 ClinGen variant curation through the VCI enables use of the nomenclature, criteria codes and  
290 rules defined in the joint 2015 ACMG/AMP guidelines on variant classification. Embedded  
291 flexibility is designed to allow biocurators to incorporate modifications and additional guidance  
292 produced by ClinGen’s Sequence Variant Interpretation WG as well as disease specifications  
293 from ClinGen VCEPs following the FDA-recognized validation process. To further aid this  
294 process, the VCI allows groups of users to curate variants as a single entity, known as an  
295 ‘affiliation’. VCI affiliations are often ClinGen Variant Curation Expert Panels (VCEPs)<sup>23,24</sup>;  
296 however, any group of users who wish to curate variants together (e.g. a clinical or research  
297 laboratory) may form an affiliation. Once a VCI user initiates a classification it belongs to that  
298 individual or affiliation, and can only be edited by them.

299

300 The ACMG/AMP guidelines provide a set of criteria to be considered when classifying a variant.  
301 The VCI is designed to help users evaluate the applicability of these criteria in an efficient and  
302 structured way (**Figure 1**). The VCI groups criteria by evidence types; displaying both the  
303 relevant criteria and any related evidence. These groups are: 1) Population (known variant allele  
304 frequencies), 2) Variant Type (predicted impact of the variant on the gene product), 3)  
305 Experimental (functional assay data), and 4) Case/Segregation (relevant observations of the  
306 variant). The VCI also groups together gene-focused resource links, and basic information,

307 displaying ClinVar and VCI curations for the variant as well as the molecular consequence of the  
308 variant on all known transcripts (**Figure 4C** and **Table 1**).

309

310 For each ACMG/AMP criteria, users are provided a description of the guideline in the VCI. The  
311 user is able to view, add and evaluate the relevant evidence, and then set their criteria evaluation  
312 and write an explanation. As some criteria are applicable at different pathogenicity strengths,  
313 users can choose the appropriate strength from a pulldown list containing only the appropriate  
314 strength options for that criterion. For instance, the available options provided for evaluating PP1  
315 are: Not Evaluated, Met, Not Met, PP1\_Moderate, and PP1\_Strong. As a user saves their  
316 evaluations, a criteria bar (**Figure 4B**) in the header of the interface keeps track of their progress  
317 by indicating which criteria have been ‘Met’ (solid color background with white criteria code),  
318 ‘Not Met’ (grey background with colored criteria code), or remain ‘Not Evaluated’ (white  
319 background with colored criteria code). If a user scrolls over individual criteria codes in this bar  
320 they will see a description for each criteria and they can click on individual criteria codes to link  
321 to the pertinent section in the VCI. Additionally, a progress bar shows the number of criteria met  
322 according to the strength of the evaluation and whether they are ‘Benign’ or ‘Pathogenic’ and  
323 also automatically calculates the pathogenicity each time an evaluation is saved or updated. At  
324 any time a user can view an ‘Evaluation Summary’ that summarizes all their evaluated evidence.  
325 If a criterion code is not evaluated then it would not be considered in the calculation of a  
326 predicted classification. Once a biocurator is satisfied they have reviewed all pertinent evidence,  
327 and evaluated all relevant criteria, they can save their classification as ‘Provisional’. This  
328 generates a PDF version of the ‘Evaluation Summary’ that can be distributed among the VCEP  
329 membership domain experts to aid in their review process. Upon satisfactory completion of the

330 review process a final classification can be saved as ‘Approved’, at which point the ‘Evaluation  
331 Summary’ can now be viewed by all VCI users.

332

333 *FDA Recognition and Data Dissemination*

334 The VCI generates an output file of the final variant pathogenicity classification in an auto-  
335 generated format compatible with ClinVar submission specifications. This is intended to  
336 facilitate timely dissemination of variant classifications to the genomics community via ClinVar  
337 and is a requirement for ClinGen VCEPs. The ultimate goal is to support fully automated, API-  
338 based ClinVar submission through the VCI once ClinVar provides support for API-based  
339 submission. Once submitted, a ‘submission to ClinVar’ (SCV) identifier is obtained and can be  
340 viewed in the VCI variant record.

341 The ClinGen variant curation process was recognized by the FDA in December 2018<sup>25</sup>, and is  
342 followed by all ClinGen VCEPs. The evidence curation data and pathogenicity classifications  
343 generated within the VCI by ClinGen VCEPs are therefore considered to be valid scientific  
344 evidence that can be used to streamline the test development and validation processes. As such,  
345 additional steps and requirements apply to the information specifically generated through the  
346 ClinGen VCEP variant curation and classification process. Specifically, all the evidence that has  
347 been curated and evaluated, along with provenance should be made publicly available and easily  
348 accessible. With this in mind the VCI saves all evidence that is evaluated by its users. In  
349 addition, upon final approval of a classification from a ClinGen VCEP, the VCI facilitates data  
350 flow to the ClinGen Evidence Repository (ERepo), where the finalized classifications and  
351 associated evidence evaluation is published. Importantly, the VCEP generated variant record in  
352 the ERepo includes comments for specific codes enabling in-depth, and transparent data for peer



353 review. (**Figure 1**). These publicly accessible displays of the final ClinGen VCEP variant  
354 classifications are accessed via the ERepo API at <https://erepo.clinicalgenome.org/evrepo/>.

355

356

### 357 *Current status and users*

358

359 VCI currently has over 1,100 registered users, two-thirds of whom are members of ClinGen  
360 VCEPs (**Figure 6**). The VCI is publicly-accessible (with registration) for variant curation. When  
361 curating together as an affiliation, all members can view and edit all information added by  
362 anyone in that affiliation. This popular feature is currently used by 79 registered affiliations,  
363 most of which represent official ClinGen VCEPs but also include other affiliations of ClinGen  
364 members (e.g. institution-specific biocurator teams) and groups unrelated to ClinGen (e.g.  
365 clinical and research laboratories).

366

### 367 **Discussion:**

368

369 Here we present the development of a genetic variant biocuration platform for health care  
370 providers, researchers and the medical genetics community to determine which gene variants are  
371 causal for a disease. The VCI supports the FDA-recognized ClinGen variant curation process and  
372 combines clinical, genetic, population, and functional evidence with expert review to classify  
373 variants into ACMG/AMP 2015 variant classification guideline categories<sup>1</sup>. Primary features of  
374 the VCI include the ability to 1) curate individually or in groups, 2) associate pertinent evidence  
375 with variant classifications, 3) allow users to assess evidence per variant curation disease/gene-

376 specific protocols, 4) enable users to save provisional records, 5) support an expert review  
377 process of curated evidence, and 6) automatically publish classifications and underlying criteria  
378 assessments to the ERepo

379

380 Future VCI improvements will focus on enhancing scale, workflow, throughput, and support  
381 ongoing compliance with FDA recognition of the ClinGen Variant Curation Expert Panels  
382 through the FDA Human Variant Database program. The current VCI v2.0 platform has over  
383 6,300 variant classifications in different curation stages, and our modernized architecture is able  
384 to scale to support over 1 million future classifications. We plan to enhance workflow usability  
385 and curation efficiency by making the platform more proactive with: 1) task management  
386 (supporting assigning of variant classification records to users) and action items (alerts to users),  
387 2) support for bulk variant curation workflows, 3) automatically bring in additional variant  
388 evidence data and monitor major data changes via a streaming service so curations can be  
389 updated as needed , and 4) provide customized curation experiences based on VCEP  
390 specifications. To ensure compliance with FDA requirements for the auditability of ClinGen  
391 variant curation process, the VCI database maintains a complete audit trail of all saved curation  
392 actions. We will further support FDA compliance with 1) additional traceability, 2) permanent  
393 archiving, 3) regular knowledge updating through literature and database monitoring, and 4)  
394 update alerts provided to curation teams.

395

396 The VCI provides needed software infrastructure and a comprehensive curation platform  
397 necessary for supporting variant classification, a critical step in the use of genomics in medicine.  
398 This global open source platform aids individual biocurators and teams of collaborating

399 biocurators in performing the complex task of variant curation in an efficient workflow to  
400 enforce rigor and quality in variant classification ultimately contributing to scientific  
401 advancement and informing health care management.

402

403 **Acknowledgements:**

404

405 All authors contributed to the project design. C.G.P., M.W.W., R.M., and H.A.C. drafted the  
406 initial version of the manuscript. All authors contributed to and approved the final version of the  
407 manuscript. We would like to thank all of the members of the Clinical Genome Resource  
408 consortium, especially the core members attending bimonthly VCI feedback meetings for their  
409 continual feedback.

410

411 **Availability:**

412

413 All code for the VCI including front-end, back-end, database schemas, analysis pipelines, and  
414 user interfaces are freely available under MIT Open Source licenses via the GitHub repositories  
415 (<https://github.com/ClinGen/> and <https://github.com/ClinGen/clincoded/>).

416

417 **References:**

- 418 1. Richards, S. *et al.* Standards and guidelines for the interpretation of sequence variants: a  
419 joint consensus recommendation of the American College of Medical Genetics and  
420 Genomics and the Association for Molecular Pathology. *Genet. Med.* **17**, 405–424 (2015).
- 421 2. Niehaus, A. *et al.* A survey assessing adoption of the ACMG-AMP guidelines for  
422 interpreting sequence variants and identification of areas for continued improvement.

- 423 *Genetics in medicine: official journal of the American College of Medical Genetics* vol. 21  
424 1699–1701 (2019).
- 425 3. Rehm, H. L. *et al.* ClinGen--the Clinical Genome Resource. *N. Engl. J. Med.* **372**, 2235–  
426 2242 (2015).
- 427 4. Amendola, L. M. *et al.* Performance of ACMG-AMP Variant-Interpretation Guidelines  
428 among Nine Laboratories in the Clinical Sequencing Exploratory Research Consortium.  
429 *Am. J. Hum. Genet.* **98**, 1067–1076 (2016).
- 430 5. Abou Tayoun, A. N. *et al.* Recommendations for interpreting the loss of function PVS1  
431 ACMG/AMP variant criterion. *Hum. Mutat.* **39**, 1517–1524 (2018).
- 432 6. Biesecker, L. G., Harrison, S. M. & ClinGen Sequence Variant Interpretation Working  
433 Group. The ACMG/AMP reputable source criteria for the interpretation of sequence  
434 variants. *Genetics in medicine: official journal of the American College of Medical Genetics*  
435 vol. 20 1687–1688 (2018).
- 436 7. Brnich, S. E. *et al.* Recommendations for application of the functional evidence PS3/BS3  
437 criterion using the ACMG/AMP sequence variant interpretation framework. *Genome Med.*  
438 **12**, 3 (2019).
- 439 8. Luo, X. *et al.* ClinGen Myeloid Malignancy Variant Curation Expert Panel  
440 recommendations for germline RUNX1 variants. *Blood Advances* vol. 3 2962–2979 (2019).
- 441 9. Lee, K. *et al.* Specifications of the ACMG/AMP variant curation guidelines for the analysis  
442 of germline CDH1 sequence variants. *Hum. Mutat.* **39**, 1553–1568 (2018).
- 443 10. Oza, A. M. *et al.* Expert specification of the ACMG/AMP variant interpretation guidelines  
444 for genetic hearing loss. *Hum. Mutat.* **39**, 1593–1613 (2018).
- 445 11. Ghosh, R. *et al.* Updated recommendation for the benign stand-alone ACMG/AMP

- 446 criterion. *Hum. Mutat.* **39**, 1525–1530 (2018).
- 447 12. Mester, J. L. *et al.* Gene-specific criteria for PTEN variant curation: Recommendations  
448 from the ClinGen PTEN Expert Panel. *Hum. Mutat.* **39**, 1581–1592 (2018).
- 449 13. Zastrow, D. B. *et al.* Unique aspects of sequence variant interpretation for inborn errors of  
450 metabolism (IEM): The ClinGen IEM Working Group and the Phenylalanine Hydroxylase  
451 Gene. *Human Mutation* vol. 39 1569–1580 (2018).
- 452 14. Gelb, B. D. *et al.* ClinGen’s RASopathy Expert Panel consensus methods for variant  
453 interpretation. *Genetics in Medicine* vol. 20 1334–1345 (2018).
- 454 15. Kelly, M. A. *et al.* Adaptation and validation of the ACMG/AMP variant classification  
455 framework for MYH7-associated inherited cardiomyopathies: recommendations by  
456 ClinGen’s Inherited Cardiomyopathy Expert Panel. *Genetics in Medicine* vol. 20 351–359  
457 (2018).
- 458 16. Tavtigian, S. V. *et al.* Modeling the ACMG/AMP variant classification guidelines as a  
459 Bayesian classification framework. *Genet. Med.* **20**, 1054–1060 (2018).
- 460 17. Landrum, M. J. *et al.* ClinVar: public archive of relationships among sequence variation and  
461 human phenotype. *Nucleic Acids Res.* **42**, D980–5 (2014).
- 462 18. Shefchek, K. A. *et al.* The Monarch Initiative in 2019: an integrative data and analytic  
463 platform connecting phenotypes to genotypes across species. *Nucleic Acids Res.* **48**, D704–  
464 D715 (2020).
- 465 19. Köhler, S. *et al.* Expansion of the Human Phenotype Ontology (HPO) knowledge base and  
466 resources. *Nucleic Acids Res.* **47**, D1018–D1027 (2019).
- 467 20. Matched Annotation from NCBI and EMBL-EBI (MANE).  
468 <https://www.ncbi.nlm.nih.gov/refseq/MANE/>.

- 469 21. Esposito, D. *et al.* MaveDB: an open-source platform to distribute and interpret data from  
470 multiplexed assays of variant effect. *Genome Biol.* **20**, 223 (2019).
- 471 22. Gelman, H. *et al.* Recommendations for the collection and use of multiplexed functional  
472 data for clinical variant interpretation. *Genome Med.* **11**, 85 (2019).
- 473 23. Harrison, S. M., Biesecker, L. G. & Rehm, H. L. Overview of Specifications to the  
474 ACMG/AMP Variant Interpretation Guidelines. *Curr. Protoc. Hum. Genet.* **103**, e93  
475 (2019).
- 476 24. Rivera-Muñoz, E. A. *et al.* ClinGen Variant Curation Expert Panel experiences and  
477 standardized processes for disease and gene-level specification of the ACMG/AMP  
478 guidelines for sequence variant interpretation. *Hum. Mutat.* **39**, 1614–1622 (2018).
- 479 25. Office of the Commissioner. FDA takes new action to advance the development of reliable  
480 and beneficial genetic tests that can improve patient care. [https://www.fda.gov/news-](https://www.fda.gov/news-events/press-announcements/fda-takes-new-action-advance-development-reliable-and-beneficial-genetic-tests-can-improve-patient)  
481 [events/press-announcements/fda-takes-new-action-advance-development-reliable-and-](https://www.fda.gov/news-events/press-announcements/fda-takes-new-action-advance-development-reliable-and-beneficial-genetic-tests-can-improve-patient)  
482 [beneficial-genetic-tests-can-improve-patient](https://www.fda.gov/news-events/press-announcements/fda-takes-new-action-advance-development-reliable-and-beneficial-genetic-tests-can-improve-patient) (2018).
- 483 26. Pawliczek, P. *et al.* ClinGen Allele Registry links information about genetic variants. *Hum.*  
484 *Mutat.* **39**, 1690–1701 (2018).
- 485 27. NCBI Resource Coordinators. Database resources of the National Center for Biotechnology  
486 Information. *Nucleic Acids Res.* **46**, D8–D13 (2018).
- 487 28. McLaren, W. *et al.* The Ensembl Variant Effect Predictor. *Genome Biol.* **17**, 122 (2016).
- 488 29. Madeira, F. *et al.* The EMBL-EBI search and sequence analysis tools APIs in 2019. *Nucleic*  
489 *Acids Res.* **47**, W636–W641 (2019).
- 490 30. Xin, J. *et al.* High-performance web services for querying gene and variant annotation.  
491 *Genome Biol.* **17**, 91 (2016).

- 492 31. Marcus, J. H. & Novembre, J. Visualizing the geography of genetic variants. *Bioinformatics*  
493 **33**, 594–595 (2017).
- 494 32. Braschi, B. *et al.* Genenames.org: the HGNC and VGNC resources in 2019. *Nucleic Acids*  
495 *Res.* **47**, D786–D792 (2019).
- 496 33. Wu, C., Macleod, I. & Su, A. I. BioGPS and MyGene.info: organizing online, gene-centric  
497 information. *Nucleic Acids Res.* **41**, D561–5 (2013).


498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526

527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543

**Figure and Figure Legends:**

**Figure 1: ClinGen FDA-Recognized Variant Curation Process and VCI.** Overview of the ClinGen Variant Curation Process using the VCI, an FDA-recognized workflow. Biocurators select a variant, and evaluate evidence that falls into six categories. VCI viewers may view all evidence available for any variant using the VCI. The VCI supports users in making a final pathogenicity classification keeping with the ACMG/AMP guidelines. ClinGen expert panels then disseminate their variant classifications through two community resources: the Evidence Repository (ERepo) and ClinVar.






544  
 545 **Figure 2: Core VCI Data Model used for storing and retrieving data as JSON documents.**

546 The VCI uses a data model centered on a classification (dark blue center box), with relationships  
 547 to other data models (white boxes). Each assertion is uniquely defined by the Variant, Disease  
 548 and Mode of Inheritance models, and is owned by a user or affiliation. It has two core attributes  
 549 a) status indicating its state in the current workflow cycle and b) selected classification (Figure  
 550 1). It uses different types of Evidence (see Evidence Collection in Figure 1) and applies an

551 Evidence Criteria to arrive at the selected classification. Each evidence type can use Articles as  
 552 supplementary evidence. As an interpretation progresses through review statuses (such as  
 553 review, approved, and published), snapshots of the full data at each review step are created. The  
 554 relationships between data models are represented here, with 1:1 (solid green lines), 1 to many  
 555 (N), or many to many (N to N) indicated.


556



557  
 558  
 559  
 560  
 561  
 562  
 563  
 564  
 565  
 566

567 **Figure 3: VCI Platform Components Overview Including Schema and Serverless**  
 568 **Architecture.** The platform is web-browser based based and uses AWS cloud services. An

569 External Resources Manager retrieves population, predictive, functional and other variant and  
570 gene-level data from external sources (**Table 1**) via APIs. In addition, the user can add in curated  
571 evidence, evaluate against ACMG/AMP guidelines and save the classification for review and  
572 approval. The approved classifications are then submitted to the ClinGen Evidence Repository.  
573 All data are saved in a database via microservices and can be accessed via queries. The Amazon  
574 Cloud Services provide the microservices to store and retrieve data adopting a Serverless  
575 Architecture utilizing the following components and services: Amplify, Cognito, API Gateway,  
576 Lambda, DynamoDB, S3, and the user-facing web interface is created using React Javascript  
577 Library.  
578



579  
 580  
 581  
 582 **Figure 4: The Basic Information View.** The VCI has six tab views that collate and display  
 583 variant information from external and internal sources to biocurators. **(A)** The top title view is  
 584 always viewable and shows the variant title, links to the variant in external resources, and key  
 585 curation information for the record. **(B)** The criteria bar displays evaluated criteria and the  
 586 calculated pathogenicity. **(C)** The basic information tab displays any curations available for the  
 587 variant in the VCI and ClinVar, and transcript information from RefSeq and Ensembl.

# NM\_004004.6(GJB2):c.110T>C (p.Val37Ala) ⓘ

[View Summary](#)

This interpretation is associated with **nonsyndromic genetic deafness**  
Autosomal recessive inheritance

### Variant ID Sources

ClinVar Variation ID: [449490](#)  
ClinGen Allele Registry ID: [CA6904317](#)  
dbSNP ID: [rs141774369](#)

### Links to External Resources

UCSC [[GRCh38/hg38](#) | [GRCh37/hg19](#)]  
Variation Viewer [[GRCh38](#) | [GRCh37](#)]  
Ensembl Browser [[GRCh38](#) | [GRCh37](#)]

### My Interpretation

**Disease:** nonsyndromic genetic deafness  
([MONDO:0019497](#))  
**Pathogenicity:** Likely pathogenic  
**Modified Pathogenicity:** Not provided  
**Provisional/Approved Status:** Published

## Variant Interpretation Record

[Disease](#) [Inheritance](#)

### Benign

No criteria met

### Pathogenic

Moderate: ⓪ Supporting: ⓪

### Calculated Pathogenicity

Likely pathogenic

BA1 BS1 BS2 BS3 BS4 BP1 BP2 BP3 BP4 BP5 BP6 BP7 PP1 PP2 **PP3** PP4 PP5 PM1 **PM2** **PM3** PM4 **PM5** PM6 PS1  
PS2 PS3 PS4 PVS1

### Basic Information

Population Variant Type Experimental Case/Segregation Gene-centric

### All interpretations for this variant in the Variant Curation Interface (VCI) ⓘ

Clinical significance	Status	Condition - Mode of inheritance	Curator/Affiliation
Likely pathogenic	<b>PUBLISHED</b>	nonsyndromic genetic deafness ( <a href="#">MONDO_0019497</a> ) - Autosomal recessive inheritance	Hearing Loss

### Overall ClinVar Interpretation [See data in ClinVar](#)

**Review status:** reviewed by expert panel **Last evaluated:** Jul 28, 2020  
**Clinical significance:** Likely pathogenic **Number of submission(s):** 4

### Interpretations Submitted to ClinVar (Germline SCVs only) ⓘ

Clinical significance (Last evaluated)	Review Status (Assertion Method)	Condition(s) (Mode of inheritance)	Submitter - Study name	Submission accession
Likely pathogenic (Jul 28, 2020)	reviewed by expert panel <a href="#">ClinGen_HL_ACMG Specifications v1</a>	Nonsyndromic hearing loss and deafness (Autosomal recessive inheritance) [MONDO: MONDO 0019497]	<a href="#">ClinGen Hearing Loss Variant Curation Expert Panel</a>	SCV001428435.1

### RefSeq Transcripts *VeIP*

Nucleotide Change	Exon	Protein Change	Molecular Consequence
NM_004004.6:c.110T>C (GJB2) <b>MANE Select</b>	2/2	NP_003995.2:p.Val37Ala	missense_variant
XM_011535049.2:c.110T>C (GJB2)	2/2	XP_011533351.1:p.Val37Ala	missense_variant

### Ensembl Transcripts *VeIP*

Nucleotide Change	Exon	Protein Change	Molecular Consequence
ENST00000382844.2:c.110T>C (GJB2)	1/1	ENSP00000372295.1:p.Val37Ala	missense_variant
ENST00000382848.5:c.110T>C (GJB2) <b>MANE Select</b>	2/2	ENSP00000372299.4:p.Val37Ala	missense_variant

589  
 590 **Figure 5: Case and Segregation Evidence Capture.** The structured data capture for the  
 591 case/segregation view in the VCI, including the (A) top title view (B) Evidence sources are  
 592 captured and structured so that users can quickly see all sources and the summed individual  
 593 counts from the pooled evidence for specific ACMG/AMP criteria (shown here is PM3).  
 594

**A**

**NM\_206933.4(USH2A):c.3407G>A (p.Ser1136Asn)** [View Summary](#)

This interpretation is associated with **Usher syndrome**  
*Autosomal recessive inheritance*

<b>Variation ID Sources</b> ClinVar Variation ID: <a href="#">133312</a> ClinGen Allele Registry ID: <a href="#">CA269917</a> dbSNP ID: <a href="#">rs483353055</a>	<b>Links to External Resources</b> UCSC [ <a href="#">GRCh38/hg38</a>   <a href="#">GRCh37/hg19</a> ] Variation Viewer [ <a href="#">GRCh38</a>   <a href="#">GRCh37</a> ] Ensembl Browser [ <a href="#">GRCh38</a>   <a href="#">GRCh37</a> ]	<b>My Interpretation</b> <b>Disease:</b> Usher syndrome ( <a href="#">MONDO:0019501</a> ) <b>Pathogenicity:</b> Likely pathogenic <b>Modified Pathogenicity:</b> Not provided <b>Provisional/Approved Status:</b> Published
--	---	--

**B**

Basic Information   Population   Variant Type   Experimental   **Case/Segregation**   Gene-centric

All information entered and accessed in the ClinGen curation interfaces should be considered publicly accessible, and may not include [protected health information \(PHI\)](#) or equivalent identifiable information as defined by regulations in your country or region. For more information about ClinGen policies on data sharing, please refer to the [Terms of Use](#).

Evidence Type		PubMed (6)					
		<a href="#">Jespersgaard C, 2019. PMID 30718709</a>	<a href="#">Huang L, 2017. PMID 28512305</a>	<a href="#">Bonnet C, 2016. PMID 27460420</a>	<a href="#">Ellingford JM, 2016. PMID 27208204</a>	<a href="#">Ta 2015. PMID 2570925</a>	
Submitted by	Sum	Hearing Loss	Hearing Loss	Hearing Loss	Hearing Loss	Lo D	
Label for case information		Jespersgaard 2018	Huang 2017	Bonnet 2016	Ellingford 2016		
<b>PM3</b>	<b># proband compound het occurrences</b>	6	1	1	1	1	
	<b>Comment</b>	677 individuals from Denmark ... <a href="#">more</a>	98 small Han Chinese families ... <a href="#">more</a>	427 individuals with Usher ... <a href="#">more</a>	105 individuals who were ... <a href="#">more</a>	71 wh ...	
	<b>Additional comments</b>	677 individuals from Denmark ... <a href="#">more</a>	98 small Han Chinese families ... <a href="#">more</a>	427 individuals with Usher ... <a href="#">more</a>	105 individuals who were ... <a href="#">more</a>	71 wh ...	

595

596


597 **Figure 6: VCI Platform growth over time. (A)** Number of curated variant classifications

598 performed in the VCI over time. **(B)** The number of biocurators and biocurator affiliations

599 accumulated over time are noted at the top of each bar.


600

601 **A**



602

603 **B**



604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626

**Tables:**

**Table 1: VCI Displayed Information Type and Source.**

Information Type	Displayed Data	Data source
------------------	----------------	-------------



Basic Information	<ul style="list-style-type: none"> <li>● Variant ID</li> <li>● HGVS terms</li> </ul>	ClinGen Allele Registry <sup>26</sup>
	<ul style="list-style-type: none"> <li>● ClinVar Variation ID</li> <li>● ClinVar Overall interpretation</li> <li>● ClinVar Submitted interpretations</li> <li>● ClinVar Primary transcript</li> <li>● RefSeq transcripts</li> <li>● dbSNP variant ID</li> <li>● Entrez Gene ID</li> </ul>	NCBI E-utilities <sup>27</sup>
	<ul style="list-style-type: none"> <li>● RefSeq transcripts</li> <li>● Ensembl transcripts</li> <li>● Molecular consequences</li> </ul>	Ensembl VEP <sup>28</sup>
	<ul style="list-style-type: none"> <li>● Monarch Disease Ontology (Mondo) human disease term(s)</li> </ul>	Ontology Lookup Service <sup>29</sup>
	<ul style="list-style-type: none"> <li>● Phenotypic abnormality term(s)</li> </ul>	Human Phenotype Ontology (HPO) <sup>19</sup>
Population	<ul style="list-style-type: none"> <li>● Allele frequencies <ul style="list-style-type: none"> <li>○ gnomAD</li> <li>○ ExAC</li> <li>○ Exome Sequencing Project</li> </ul> </li> </ul>	MyVariant.info <sup>30</sup>
	<ul style="list-style-type: none"> <li>● Allele frequencies <ul style="list-style-type: none"> <li>○ PAGE Study</li> </ul> </li> </ul>	GGV Browser <sup>31</sup>
	<ul style="list-style-type: none"> <li>● Allele frequencies <ul style="list-style-type: none"> <li>○ 1000 Genomes</li> </ul> </li> </ul>	Ensembl VEP <sup>28</sup>
Variant Type	<ul style="list-style-type: none"> <li>● <i>In silico</i> predictor scores <ul style="list-style-type: none"> <li>○ REVEL</li> <li>○ SIFT</li> <li>○ PolyPhen2</li> <li>○ LRT</li> <li>○ MutationTaster</li> <li>○ MutationAssessor</li> <li>○ FATHMM</li> <li>○ PROVEAN</li> <li>○ MetaSVM</li> <li>○ MetaLR</li> <li>○ CADD</li> <li>○ FATHMM-MKL</li> <li>○ fitCons</li> </ul> </li> <li>● Conservation analysis scores</li> </ul>	MyVariant.info <sup>30</sup>

	<ul style="list-style-type: none"> <li>○ phyloP100way</li> <li>○ phyloP30way</li> <li>○ phastCons100way</li> <li>○ phastCons30way</li> <li>○ GERP++</li> <li>○ SiPhy</li> </ul>	
Experimental	<ul style="list-style-type: none"> <li>● Experimental functional data</li> </ul>	ClinGen Functional Data Repository (FDRepo)
Gene-Centric	<ul style="list-style-type: none"> <li>● Gene symbol</li> </ul>	HGNC <sup>32</sup>
	<ul style="list-style-type: none"> <li>● ExAC constraint scores</li> <li>● UniProt protein ID</li> <li>● GeneCards gene</li> </ul>	MyGene.info <sup>33</sup>

627  
628  
629  
630